Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis

Pastor, Marta; Moreno-Sastre, María; Esquisabel, Amaia; Sans, Eulàlia; Viñas, Miguel; Bachiller, Daniel; Asensio, Víctor J.; Pozo, Ángel del; Gaínza, Eusebio; Pedraz, José Luís

doi:10.1016/j.ijpharm.2014.10.048

Cited by 59 publications

(35 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were characterized for size, polydispersity index (PDI), and Zeta potential by means of Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Encapsulation efficiency and release profile were determined by HPLC as reported elsewhere [18].…”

Section: Characterization Of Lipid Nanoparticlesmentioning

confidence: 99%

“…The use of nanoparticles could overcome pre-existing drug resistance mechanisms, including decreased uptake and increased efflux of drug as well as biofilm formation [16,17]. The in vitro activity of sodium colistimethate on similar isolates in planktonic form was reported recently [18]. Lipid nanoparticles loaded with aminoglycosides are significantly more effective than free formulations against P. aeruginosa clinical isolates [19,20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients

Sans-Serramitjana

Fusté

Martínez-Garriga

et al. 2016

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Pseudomonas aeruginosa frequently infects the respiratory tract of cystic fibrosis (CF) patients. Multidrug-resistant phenotypes and high capacity to form stable biofilms are common. Recent studies have described the emergence of colistin-resistant isolates in CF patients treated with long-term inhaled colistin. The use of nanoparticles containing antimicrobials can contribute to overcome drug resistance mechanisms. The aim of this study was to explore antimicrobial activity of nanoencapsulated colistin (SLN-NLC) versus free colistin against P. aeruginosa clinical isolates from CF patients and to investigate their efficacy in biofilm eradication. Susceptibility of planktonic bacteria to antimicrobials was examined by using the broth microdilution method and growth curve assay. Minimal biofilm eradication concentration (MBEC) and biofilm prevention concentration (BPC) were determined to assess antimicrobial susceptibility of sessile bacteria. We used atomic force microscopy (AFM) to visualize treated and untreated biofilms and to determine surface roughness and other relevant parameters. Colistin nanoparticles had the same antimicrobial activity as free drug against planktonic bacteria. However, nanoencapsulated colistin was much more efficient in the eradication of biofilms than free colistin. Thus, these formulations have to be considered as a good alternative therapeutic option to treat P. aeruginosa infections.

show abstract

Section: Characterization Of Lipid Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients

Sans-Serramitjana

Fusté

Martínez-Garriga

et al. 2016

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…In our previous works, 16,18 we demonstrated the identical antimicrobial activity of free colistin and NLC-colistin. Here we have shown that NLC-colistin was clearly more effective than its free form in eradicating biofilms of P. aeruginosa, the most relevant pathogen in CF patients.…”

Section: Resultsmentioning

confidence: 57%

“…18 The lipid core consisted of Precirol ® ATO 5 (Gattefossé, Madrid, Spain) and Miglyol 812 (Sasol, Hamburg, Germany), which were mixed with colistin sulfate (Zhejiang Shenghua Biok Biology Co., Ltd., China). The temperature of the mixture was gradually increased to the melting temperature of the solid lipids.…”

Section: Preparation Of Lipid Nanoparticlesmentioning

confidence: 99%

Determination of the spatiotemporal dependence of <em>Pseudomonas aeruginosa</em> biofilm viability after treatment with NLC-colistin

Sans-Serramitjana¹,

Jorba²,

Pedraz³

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

The emergence of colistin-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients, particularly after long-term inhalation treatments, has been recently reported. Nanoen-capsulation may enable preparations to overcome the limitations of conventional pharmaceutical forms. We have determined the time-dependent viability of P. aeruginosa biofilms treated with both free and nanoencapsulated colistin. We also examined the relationship between the optimal anti-biofilm activity of nanostructured lipid carrier (NLC)-colistin and the structural organization of the biofilm itself. The results showed the more rapid killing of P. aeruginosa bacterial biofilms by NLC-colistin than by free colistin. However, the two formulations did not differ in terms of the final percentages of living and dead cells, which were higher in the inner than in the outer layers of the treated biofilms. The effective anti-biofilm activity of NLC-colistin and its faster killing effect recommend further studies of its use over free colistin in the treatment of P. aeruginosa infections in CF patients.

show abstract

“…Radiography-confirmed diagnosis, low FEV 1 and presence of PA in sputum were the only criteria for inclusion. Using a measure such as the recently widely Aminoglycoside Gentamicin Dry powder [84] Tobramycin PLGA z dry powder [85] Tobramycin Liposomal z dry powder [86,87] Macrolide Clarithromycin Sprayed liquid [43] Clarithromycin PLGA z dry powder [44] Clarithromycin Liposomal z suspension * [88] Telithromycin Sprayed liquid [45] Azithromycin Nebulised solution [46] Azithromycin Dry powder [89] Fluoroquinolone Ciprofloxacin Dry powder [90] Ciprofloxacin PLGA z dry powder [91] Ciprofloxacin Liposomal z suspension * [92] Polymyxins Colistin (colistimethate sodium) Liposomal z suspension * [93] Polymyxin B Liposomal z suspension * [54] Combination Doxycycline and ciprofloxacin Dry powder [94,95] Ciprofloxacin and gatifloxacin (with ambroxol) Dry powder [82,96] Vancomycin and clarithromycin Dry powder [97] Tobramycin and clarithromycin Dry powder [98] validated bronchiectasis severity index (BSI) [58] may help stratify patients' disease severities, which may allow degree of benefit to be more accurately determined. This measure is described more thoroughly in Section 4.1.…”

Section: Methodsmentioning

confidence: 99%

Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives

Sugianto

Chan

2015

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

The evidence base of the clinical efficacy of inhaled antibiotics in NCFB is limited and the degrees of reported clinical benefits have been modest and conflicting. Challenges surrounding inhaled antibiotics application and development include the lack of knowledge of disease factors and optimum management strategies, unreceptive lung pathophysiology and the lack of factors that support compliance and tolerability. Nonetheless, research continues to give birth to new clinical findings and novel formulations such as combination antibiotics and sustained-release formulations, which add great value to the development of efficacious, safe and convenient inhalable antibiotics of the future.

show abstract

Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis

Cited by 59 publications

References 35 publications

Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients

Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients

Determination of the spatiotemporal dependence of <em>Pseudomonas aeruginosa</em> biofilm viability after treatment with NLC-colistin

Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives

Contact Info

Product

Resources

About